- Profile
- prev
- next
General
-
Headquarters
Alameda, California, United States
-
Founders & Team
Michael West
-
Year Founded
2017
-
Company type
Public company
-
Stock Ticker
NYSE:AGE
-
Funding stage
IPO
-
Total funding ($M)
63.8
-
Investors
Juvenescence
Technical Details
-
Aging Target
Cell Loss
-
Product modality
stem cells, tissue regeneration
-
Clinical stage
Pre-clinical
About
AgeX Therapeutics is focused on the development and commercialization of novel therapeutics targeting human aging. We are building upon the foundation of our proprietary technologies such as PureStem® and induced Tissue Regeneration (iTR™) to develop innovative medicines designed to address some of the largest unsolved problems in aging. Through PureStem® we have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is our revolutionary longevity platform aiming to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.